CytoReason Team (Facebook)
CytoReason, an Israeli startup, empowers drug development leaders with AI-powered insights, accelerating decision-making and optimizing R&D portfolios to increase Phase 2 Success Rates. To further that goal, and to establish a US Hub in Cambridge, Massachusetts, the company raised $80 million from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher.
The new funding comes after in May CytoReason entered a strategic collaboration with the Crohn’s & Colitis Foundation to empower CytoReason’s analytical capabilities with the Foundation’s IBD Plexus real-world data platform. This collaboration has the potential to accelerate new discoveries with superior data integration and improve the precision and effectiveness of drug development in inflammatory bowel disease (IBD).
As part of the collaboration, the Foundation’s IBD Plexus®real-world data platform, comprising thousands of patient intestinal biopsies and comprehensive real-world data, will be integrated into CytoReason’s pre-computed disease model platform.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Founded in 2016, CytoReason is a tech company developing a computational model of the human body. The company collects proprietary data from pharma companies and uses it to simulate human diseases – tissue by tissue, cell by cell. With CytoReason’s database and AI-led platform, pharma and biotech companies identify new opportunities, shorten trial phases, reduce development costs and increase the likelihood of drug approval. To date, five of the world’s top ten pharma companies use CytoReason’s technology.
Since the company announced the expansion of its Pfizer partnership in 2022, CytoReason has added three major pharma partnerships, expanded its coverage of disease models to central nervous system (CNS)-related diseases, and partnered with leading data organizations.
David Harel, Co-founder and CEO of CytoReason, said, “CytoReason is grateful for this infusion of new capital from industry technology powerhouses such as NVIDIA, Pfizer, and Thermo Fisher. The world understands that data alone is not enough, and that the future of data-driven insights is in data modeling. CytoReason is at the forefront of this revolution in pharma R&D.”
